View ValuationMangoceuticals 将来の成長Future 基準チェック /06現在、 Mangoceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Consumer Retailing 収益成長8.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesMangoceuticals, Inc. announced delayed annual 10-K filingApr 01Mangoceuticals, Inc. Announces Pct Patent Filing for Mgx-0024 Antiviral TechnologyMar 07Mangoceuticals, Inc. Announces New Data from its Prophylactic Compound MGX-0024Feb 24Mangoceuticals, Inc. Receives a Deficiency Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketFeb 07New major risk - Market cap size Dec 21Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.499995 million.Dec 19+ 1 more updateChief Financial Officer notifies of intention to sell stock Dec 04Independent Director recently sold US$153k worth of stock Nov 28Independent Director notifies of intention to sell stock Nov 20New major risk - Financial position Nov 17Third quarter 2025 earnings released: US$0.69 loss per share (vs US$0.99 loss in 3Q 2024) Nov 17New major risk - Financial position Aug 15Second quarter 2025 earnings released: US$0.54 loss per share (vs US$1.37 loss in 2Q 2024) Aug 15Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 28+ 1 more updateFirst quarter 2025 earnings released: US$1.05 loss per share (vs US$1.56 loss in 1Q 2024) May 16New major risk - Market cap size Apr 06New major risk - Share price stability Mar 25New major risk - Revenue and earnings growth Mar 21Full year 2024 earnings released: US$4.40 loss per share (vs US$8.58 loss in FY 2023) Mar 21Mangoceuticals, Inc. Advances Antiviral Research on its Patented Respiratory Illness Prevention TechnologyFeb 12New minor risk - Share price stability Feb 08Mangoceuticals, Inc. Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 StudiesFeb 06Third quarter 2024 earnings released: US$0.99 loss per share (vs US$1.70 loss in 3Q 2023) Nov 17Mangoceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementOct 31Mangoceuticals, Inc. Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss SolutionsOct 03Mangoceuticals, Inc. Launches 'Slim' Oral Semaglutide Weight Loss TreatmentOct 02Second quarter 2024 earnings released: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023) Aug 16Mangoceuticals, Inc. Announces Successful Migration to Its Newly Developed DEA -Approved Telemedicine Operating SystemAug 09MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via SurescriptsJul 17Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation DepartmentJul 13Independent Director notifies of intention to sell stock Jun 23Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care TechnologyJun 08Mangorx to Introduce “Mojo” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone ImbalancesJun 05New major risk - Shareholder dilution May 27First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2023) May 16Mangoceuticals, Inc., Annual General Meeting, Jun 17, 2024May 05Mangoceuticals, Inc. Provides Non-Compliance UpdateMay 03New major risk - Shareholder dilution Apr 14New major risk - Financial position Apr 09Mangoceuticals, Inc. Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy TreatmentMar 14Mangoceuticals, Inc. Accepting Pre Orders for its PRIMEFeb 06High number of new and inexperienced directors Dec 31Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.2 million.Dec 20Mangoceuticals, Inc. to Introduce “Prime”, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy (TRT) ProductDec 14Mangoceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.6 million.Dec 12Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRxNov 18Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLCNov 09Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)Nov 02New major risk - Share price stability Oct 12New major risk - Market cap size Oct 10Mangoceuticals, Inc. Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid DissolveAug 17Mangoceuticals, Inc. Announces Upcoming Launch of Its Sildenafil Based Mango Flavored Rapid Dissolve ED ProductJun 22Mangoceuticals, Inc. Appoints Aaron Andrew to Its Advisory BoardMay 27Mangoceuticals, Inc. Appoints Amanda Hammer as New Chief Operating OfficerMay 05 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Mangoceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NasdaqCM:MGRX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-22-6-6N/A9/30/20250-21-6-6N/A6/30/20251-15-6-6N/A3/31/20251-12-6-6N/A12/31/20241-10-5-5N/A9/30/20241-10-5-5N/A6/30/20241-9-6-6N/A3/31/20241-9-6-6N/A12/31/20231-9-7-7N/A9/30/20230-7-6-6N/A6/30/20230-6-5-5N/A3/31/20230-5-3-3N/A12/31/20220-2-1-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MGRXの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MGRXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MGRXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MGRXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MGRXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MGRXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 09:31終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mangoceuticals, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Mangoceuticals, Inc. Receives a Deficiency Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketFeb 07
Mangoceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.499995 million.Dec 19+ 1 more update
Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian FluMay 28+ 1 more update
Mangoceuticals, Inc. Advances Antiviral Research on its Patented Respiratory Illness Prevention TechnologyFeb 12
Mangoceuticals, Inc. Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 StudiesFeb 06
Mangoceuticals, Inc. Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss SolutionsOct 03
Mangoceuticals, Inc. Announces Successful Migration to Its Newly Developed DEA -Approved Telemedicine Operating SystemAug 09
Mangoceuticals, Inc.Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation DepartmentJul 13
Mangoceuticals, Inc. Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care TechnologyJun 08
Mangorx to Introduce “Mojo” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate and Pregnenolone for Treatment of Low Testosterone and Male Hormone ImbalancesJun 05
Mangoceuticals, Inc. Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex® FDA Approved Oral Testosterone Replacement Therapy TreatmentMar 14
Mangoceuticals, Inc. to Introduce “Prime”, Powered by Kyzatrex® (Ciii Testosterone Undecanoate Capsules), for an FDA Approved Oral Testosterone Replacement Therapy (TRT) ProductDec 14
Mangoceuticals Expands its Men's Health Product Line with Compounded Hair Growth Treatment 'Grow' by MangoRxNov 18
Mangoceuticals, Inc. Receives an Expected Letter from Listing Qualifications Department of The Nasdaq Stock Market LLCNov 09
Mangoceuticals Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirements Set Forth in Nasdaq Listing Rule 5550(a)(2)Nov 02
Mangoceuticals, Inc. Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid DissolveAug 17
Mangoceuticals, Inc. Announces Upcoming Launch of Its Sildenafil Based Mango Flavored Rapid Dissolve ED ProductJun 22